{'fraction_non_alphanumeric': 0.01393188854489164, 'fraction_numerical': 0.0, 'mean_word_length': 5.670103092783505, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
New treatments in scleroderma: dermatologic perspective

Although much is known about the pathogenesis of scleroderma, there are no established treatment modalities for SSc. The agents presently used targeting vascular abnormalities, fibrosis and/or having cytotoxic or immunosuppressive activities, in controlled studies did not prove to be sufficiently effective. However in individual cases of SSc a symptomatic improvement in skin indurations could be usually achieved. There is still no universal therapy for SSc and due to a great individual variability of disease progression the evaluation of any type of treatment is extremely difficult.